You have been chosen to receive this valuable information.

A SPECIAL ANNOUNCEMENT FROM:     Download Deals & Portfolio Review Executive Summary Know the Landscape, Get the Deal A look at what’s ahead for 2019 Download Report Today Cortellis 2018 Deals & Portfolio Review Get the latest insights. 2018 saw a staggering $428B worth of Biopharma deals. Are you in the right conversations with the right data to make the right deal? You will get vital intelligence on: • the oncology landscape, which remained the strongest area for deals • the drivers behind a record-breaking year of FDA NME approvals increasing importance in drug development and dealmaking • many more essential insights to put you into the right deals with the right partners Position your next deal armed with an understanding of the market’s largest and most influential transactions and acquisitions. Download the Cortellis 2018 Deals & Portfolio Review Executive Summary now. Key statistics: 4,014 total deals took place in 2018, valued at $428B Driven by competitive intensity in areas such as oncology and rare diseases and a focus on early-stage assets. Overall deal values rose 9% FROM $392B TO $428B The top five therapeutic M&A deals alone totaled a staggering $104.6B. Follow us: © 2019 Clarivate Analytics Manage your preferences Privacy policy 1500 Spring Garden Street Fourth Floor Philadelphia PA 19130, USA

Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Applied Clinical Trials, a UBM publication. You are on the mailing list as %%emailaddress%%.